Fennec Pharmaceuticals Inc.

NasdaqCM FENC

Fennec Pharmaceuticals Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2024: USD 2.84 M

Fennec Pharmaceuticals Inc. EBIT is USD 2.84 M for the Trailing 12 Months (TTM) ending September 30, 2024, a 115.82% change year over year. EBIT means earnings before interest and taxes, it is calculated as operating income plus non-operating income.

Fennec Pharmaceuticals Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2023 was USD -17.93 M, a 13.61% change year over year.
Fennec Pharmaceuticals Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2022 was USD -20.75 M, a -5.84% change year over year.
Fennec Pharmaceuticals Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2021 was USD -19.61 M, a -5.25% change year over year.
Fennec Pharmaceuticals Inc. EBIT for the Trailing 12 Months (TTM) ending September 30, 2020 was USD -18.63 M, a 19.27% change year over year.

Key data

Date	EBIT	EBITDA	Net Income	EPS (Diluted)

NasdaqCM: FENC

Fennec Pharmaceuticals Inc.

CEO	Mr. Rostislav Raykov
IPO Date	Sept. 15, 2017
Location	United States
Headquarters	68 TW Alexander Drive
Employees	29
Sector	Health Care
Industries Pharmaceuticals Biotechnology

Description

Fennec Pharmaceuticals Inc. operates as a biopharmaceutical company. Its product candidate in the clinical stage of development is PEDMARK, a formulation of sodium thiosulfate for the prevention of platinum-induced ototoxicity in pediatric cancer patients. The company was formerly known as Adherex Technologies Inc. and changed its name to Fennec Pharmaceuticals Inc. in September 2014. Fennec Pharmaceuticals Inc. was incorporated in 1996 and is based in Research Triangle Park, North Carolina.

Key trends

Past 5 years